Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. (Q53875366)

21 May 2018

title

Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. (English)

1 reference

21 May 2018

author

Ziad Nahas

7

1 reference

21 May 2018

Sarah H. Lisanby

8

object named as

Sarah H Lisanby

1 reference

21 May 2018

2

A John Rush

2 references

ORCID Public Data File 2021

21 May 2018

author name string

Lauren B Marangell

1

1 reference

21 May 2018

Mark S George

3

1 reference

21 May 2018

Harold A Sackeim

4

1 reference

21 May 2018

Christopher R Johnson

5

1 reference

21 May 2018

Mustafa M Husain

6

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 February 2002

1 reference

21 May 2018

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Biological Psychiatry

1 reference

21 May 2018

volume

51

1 reference

21 May 2018

issue

4

1 reference

21 May 2018

page(s)

280-287

1 reference

21 May 2018

Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Loss of Antidepressant Efficacy During Maintenance Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Continuation Therapy with Amitriptyline in Depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Three-year outcomes for maintenance therapies in recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Development of a Rating Scale for Primary Depressive Illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

A New Depression Scale Designed to be Sensitive to Change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Placebos, drug effects, and study design: a clinician's guide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Loss of drug effects during continuation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

The MOS 36-ltem Short-Form Health Survey (SF-36)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

A Structured Interview Guide for the Hamilton Depression Rating Scale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

A rating scale for mania: reliability, validity and sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901343-9

10.1016/S0006-3223(01)01343-9

7 January 2021

Identifiers

DOI

1 reference

21 May 2018

PubMed ID

11958778

1 reference

21 May 2018